Products
Platform
Research
Market
Learn
Compare HDFC Pharma And Healthcare Fund vs SBI Healthcare Opportunities Fund
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Fund Details
Risk | Very High | Very High |
Rating | - | 5.0 |
Min SIP Amount | ₹100 | ₹500 |
Expense Ratio | 2.08 | 1.94 |
NAV | ₹17.07 | ₹427.18 |
Fund Started | 14 Sep 2023 | 04 Jun 1999 |
Fund Size | ₹1936.05 Cr | ₹4026.55 Cr |
Exit Load | Exit load of 1%, if redeemed within 30 days. | Exit load of 0.50% if redeemed within 15 days |
Risk
Very High
Very High
Rating
-
5.0
Min SIP Amount
₹100
₹500
Expense Ratio
2.08
1.94
NAV
₹17.07
₹427.18
Fund Started
14 Sep 2023
04 Jun 1999
Fund Size
₹1936.05 Cr
₹4026.55 Cr
Exit Load
Exit load of 1%, if redeemed within 30 days.
Exit load of 0.50% if redeemed within 15 days
Returns
1 Year | 14.85% | 11.27% |
3 Year | - | 26.29% |
5 Year | - | 20.52% |
1 Year
14.85%
11.27%
3 Year
-
26.29%
5 Year
-
20.52%
Holding Analysis
Equity | 97.93% | 96.98% |
Cash | 2.07% | 2.94% |
Equity
97.93%
96.98%
Cash
2.07%
2.94%
Top Holdings
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 11.68% |
Divi's Laboratories Ltd. | 10.06% |
Cipla Ltd. | 6.87% |
Lupin Ltd. | 5.60% |
Glenmark Pharmaceuticals Ltd. | 5.53% |
Ipca Laboratories Ltd. | 4.47% |
Torrent Pharmaceuticals Ltd. | 3.83% |
Krishna Institute of Medical Sciences Ltd | 3.71% |
Eris Lifesciences Ltd. | 3.60% |
Aster DM Healthcare Ltd. | 3.59% |
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 12.19% |
Divi's Laboratories Ltd. | 7.78% |
Max Healthcare Institute Ltd. | 6.96% |
Lonza Group Ag | 4.76% |
Cipla Ltd. | 4.69% |
Lupin Ltd. | 4.23% |
Mankind Pharma Ltd. | 3.37% |
Abbott India Ltd. | 3.34% |
Fortis Healthcare Ltd. | 3.30% |
Aster DM Healthcare Ltd. | 3.25% |
Fund Manager
Name | Dhruv Muchhal | Tanmaya Desai |
Start Date | 14 Sep 2023 | 27 Jun 2011 |
Name
Dhruv Muchhal
Tanmaya Desai
Start Date
14 Sep 2023
27 Jun 2011
About Fund
Description | The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies. | The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space. |
Launch Date | 14 Sep 2023 | 04 Jun 1999 |
Description
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.
Launch Date
14 Sep 2023
04 Jun 1999
